Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the ...

Having close family and friends who care about their health makes women more likely to get regularly screened for cancer, a ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

Only 15% of those who start a glucagon-like peptide 1 (GLP-1) for weight loss are still taking it two years according to ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...

A trade organization representing compounding pharmacies that make unbranded versions of the weight loss drugs Mounjaro and ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

As the demand for weight loss injectables soars, so too does the market for off-brand alternatives, some of which may not be safe or effective.

Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...